SEARCH:   Advanced

Blood, 30 April 2009, Vol. 113, No. 18, pp. 4171-4178. Prepublished online as a Blood First Edition Paper on January 8, 2009; DOI 10.1182/blood-2008-09-178541. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-09-178541v1 113/18/4171    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tam, C. S. Articles by Verstovsek, S. Search for Related Content PubMed PubMed Citation Articles by Tam, C. S. Articles by Verstovsek, S. Related Collections Myeloid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course Constantine S. Tam1, Lynne V. Abruzzo2, Katherine I. Lin1, Jorge Cortes1, Alice Lynn1, Michael J. Keating1, Deborah A. Thomas1, Sherry Pierce1, Hagop Kantarjian1, and Srdan Verstovsek1 Departments of 1 Leukemia and 2 Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 ± one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. S. Tam, H. Kantarjian, J. Cortes, A. Lynn, S. Pierce, L. Zhou, M. J. Keating, D. A. Thomas, and S. Verstovsek Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis J. Clin. Oncol., November 20, 2009; 27(33): 5587 - 5593. [Abstract] [Full Text] [PDF] P. Guglielmelli, G. Barosi, G. Specchia, A. Rambaldi, F. Lo Coco, E. Antonioli, L. Pieri, A. Pancrazzi, V. Ponziani, F. Delaini, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele Blood, August 20, 2009; 114(8): 1477 - 1483. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020